KEM Hospital, Pune pioneered the development of specialised Nephrology in 1969 with the establishment of the first dialysis unit in Maharashtra, after Mumbai. In 2013 an additional specialised paediatric nephrology service was added to the Renal Unit.
The Unit conducts diverse research including single centre studies in haemodialysis, acute kidney injury, and genetic and functional studies in haemolytic uremic syndrome (HUS). It has collaborated and participated in multicentre national and international studies relating to maintenance haemodialysis, acute kidney injury biomarkers with the AKIN network, and genetic studies with KEM Hospital Mumbai and MPUH Nadiad.
Specific research areas in paediatric nephrology include renal involvement in Wilson’s Disease, ambulatory blood pressure monitoring (ABPM) in diagnosis of hypertension in children with solitary functioning kidneys, and prevalence of haematological abnormalities in distal RTA.
Recently, the Unit participated in a multicentric trial: Optimal Dose of Cholecalciferol Supplementation in Children with Chronic Kidney Disease – An Open Label Randomised Control Trial.
Researchers Team
Dr. Valentine Lobo
Dr. Ashish Bavdekar
Dr. Jyoti Sharma
Dr. Vipul Chakurkar
Sr.No.
Study Title
Principal Investigator
Duration
Ongoing / Closed
01
A multicentre, randomised, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
A multicentre, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
A multicentric, randomised, prospective, double blind, parallel group, comparative, active controlled, phase III clinical study to evaluate the efficacy, safety and tolerability of Fixed Dose Combination of Dapagliflozin 10 mg and Telmisartan 80 mg versus concurrent use Dapagliflozin 10mg tablets and Telmisartan 80mg tablets in patients with chronic kidney disease.
A multicentre, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy
